Healthcare
Commented by Carsten Mainitz on April 10th, 2026 | 08:20 CEST
Unlocking Massive Potential in Pharma's Largest Segment: Innovator Vidac Pharma, Industry Leader Bayer, or Turnaround Candidate Evotec?
Oncology is the most strategically important growth market in the pharmaceutical industry and at the same time one of the key levers for improving global health. Currently, around 20 million people worldwide are diagnosed with cancer each year, a figure expected to exceed 30 million annually by 2040. The global oncology drug market is already valued at over USD 200 billion and continues to expand rapidly. Bayer aims to rank among the world's leading oncology players by 2030 and recently reaffirmed its medium-term targets. Following the sale of a stake in a cancer specialist, shareholders of Evotec, which has faced significant pressure, may soon benefit from a welcome inflow of funds. Vidac Pharma, on the other hand, is breaking new ground in the fight against skin cancer. There is enormous potential here.
Read
Commented by Stefan Feulner on April 10th, 2026 | 07:05 CEST
Strategy, Aspermont, Redcare Pharmacy – Turnaround Opportunities Back in Focus
Markets are increasingly pricing in comeback potential. While the largest cryptocurrency climbs back above USD 70,000 and institutional inflows provide a tailwind, some players are unwaveringly betting on expansion despite billions in losses. At the same time, a data-driven platform model in the commodities sector is gaining traction, with over 180% upside potential, driven by scalable revenues and growing demand. In the e-commerce healthcare market, too, an operational turnaround following a prolonged period of weakness is triggering double-digit price movements. The combination of turnaround dynamics, oversold valuations, and long-term growth drivers could set the stage for further upside.
Read
Commented by Fabian Lorenz on February 17th, 2026 | 07:55 CET
Buy this stock NOW? Gerresheimer, TUI, and Silver Viper Minerals!
If you missed the silver rally, the current consolidation could offer an interesting entry opportunity - and potentially a chance to add to positions. One intriguing second-tier stock in this context is Silver Viper Minerals. In a compelling interview, the CEO outlines the company's strengths. Could it soon become the largest explorer in Mexico? At first glance, the sharp drop in Gerresheimer’s share price might argue in favor of a buying opportunity. However, there are significant concerns. The company’s accounting practices remain subject to scrutiny, and now operational performance is also showing signs of weakness. In contrast, TUI appears to be performing solidly. The tourism group is paying dividends again and has had a strong start to the new year. While the share price has edged slightly lower, insiders have been buying.
Read
Commented by Carsten Mainitz on February 12th, 2026 | 07:55 CET
Watch out! Gerresheimer slumps 30%, NEO Battery Materials as a game changer, Schott Pharma surprises positively
Many stories of success and failure are written on the stock market. NEO Battery Materials, the game changer in battery technology, is particularly exciting. The Canadian company offers manufacturers of drones, robots, and electric vehicles customizable high-performance batteries produced in the West. With its innovative approach, the company is setting new standards in terms of performance, charging speed, and price, thereby addressing a huge market that experts estimate will grow to around USD 30 billion by 2032. The examples of Gerresheimer and Schott Pharma show how differently companies in the same industry can develop: Schott exceeded market expectations in the first quarter, while Gerresheimer shocked the markets once again.
Read
Commented by Armin Schulz on January 8th, 2026 | 07:05 CET
How to benefit from the healthcare industry's comeback in 2026: Novo Nordisk, Vidac Pharma, and Pfizer in focus
After a disappointing year for investors in the pharmaceutical and biotech industries, the tide is now turning decisively on the stock market for these stocks. Political clarity, a return to major acquisitions, and groundbreaking clinical data are laying the foundation for a sustainable comeback. This new optimism is opening up concrete opportunities for strategic investments. Three companies exemplify these promising drivers: Novo Nordisk, Vidac Pharma, and Pfizer.
Read
Commented by Armin Schulz on December 2nd, 2025 | 07:00 CET
The demographic clock is ticking: How Bayer, Vidac Pharma, and Novo Nordisk are positioning themselves in the billion-dollar battle for our health
The demographic clock is ticking inexorably. An aging society brings with it a flood of widespread diseases such as heart disease, cancer, and diabetes. Each one is a billion-dollar market that is pushing healthcare systems to their limits. As costs explode, brutal, cut-throat competition is emerging. The winner will not be the one with the most pills, but the one with the most effective solutions to the greatest medical and economic challenges of our time. Today, we take a look at how Bayer, Vidac Pharma, and Novo Nordisk plan to shape the future.
Read
Commented by Nico Popp on October 31st, 2025 | 07:00 CET
Health as a billion-dollar market: PanGenomic Health, Hims & Hers, WW International
More and more people are taking a proactive approach to their health, with prevention and self-care trending. According to recent studies by McKinsey, the global wellness industry is now valued at around USD 2 trillion. Younger generations in particular are integrating health firmly into their lifestyles: nearly 30% of millennials and Gen Z in the US report that they are doing significantly more for their well-being today than they were a year ago. Instead of only taking action when they fall ill, many are focusing on prevention, digital health tools, and online communities for support and exchange. We take a look at the latest trends, revisit familiar names, and highlight an emerging startup that could also deliver healthy returns for your portfolio.
Read
Commented by Armin Schulz on October 20th, 2025 | 07:05 CEST
Why this structural change in medicine makes Novo Nordisk, PanGenomic Health, and Pfizer must-haves
The medicine of tomorrow does not think in terms of diseases but in terms of opportunities. A radical shift from repair to proactive prevention is revolutionizing the healthcare sector and opening up massive areas of growth. The focus is on personalized, data-driven solutions that improve quality of life and combat widespread diseases costing billions. This structural transformation is creating clear winners, led by pioneers who have mastered the new logic of the healthcare market. Three companies that embody this trend and make it tangible for investors are Novo Nordisk, PanGenomic Health, and Pfizer.
Read
Commented by André Will-Laudien on September 29th, 2025 | 07:20 CEST
Attention: Acquisitions! Biotechs like Evotec, PanGenomic Health, Pfizer, and BioNTech in focus
The biotech industry is in turmoil! With the expiration of blockbuster patents, there is a threat of sharp declines in revenue, which must be strategically compensated for. Driven by economic pressure and a growing focus on innovation and technology, the industry is increasingly turning to acquisitions of biotech companies with promising drug candidates, new technologies, and digital expertise. Not only are entire pipelines being acquired, but key players from the fastest-growing segments are also being targeted, particularly in the field of obesity therapies, where billions are being paid for drug candidates. Several examples illustrate this wave of transformation. Companies are restructuring, focusing their activities, and rapidly preparing for a phase of sustainable growth. The pace is picking up! Here are some promising investment ideas!
Read
Commented by Carsten Mainitz on September 26th, 2025 | 07:35 CEST
Gerresheimer, dynaCERT, Volkswagen – Exciting developments!
News drives prices. However, the pendulum can swing in both directions. For informed investors, the correct interpretation of events is crucial. Often, this then leads to lucrative entry and exit signals. Gerresheimer was the latest to be hit, but which stock could be next? However, there are also stocks that are due for a realignment, offering opportunities for rising prices.
Read